Pulmonary vasodilators

Respiratory Care

Volumn 52, Issue 7, 2007, Pages 885-899

  Siobal, Mark S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Calcium channel blockers; Endothelin receptor antagonists; Nitric oxide; Nitric oxide donors; Oxygen; Phosphodiesterase inhibitors; Prostacyclins; Pulmonary vasodilators

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DARUSENTAN; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; ILOPROST; MILRINONE; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN; PROSTAGLANDIN E1; SILDENAFIL; SITAXSENTAN; TADALAFIL; TOLAFENTRINE; UNCLASSIFIED DRUG; UNIPROST; VARDENAFIL; VASODILATOR AGENT; ZAPRINAST;

ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ARTIFICIAL VENTILATION; CATHETER INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYANIDE POISONING; DEEP VEIN THROMBOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; EXTRACORPOREAL OXYGENATION; FIBROSING ALVEOLITIS; FLUSHING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HUMAN; HYPOTENSION; HYPOXEMIA; HYPOXIA; HYPOXIC LUNG VASOCONSTRICTION; INJECTION SITE PAIN; INTERMETHOD COMPARISON; LIVER FUNCTION; LIVER TOXICITY; LOW DRUG DOSE; LUNG CIRCULATION; LUNG DYSPLASIA; LUNG EDEMA; LUNG EMBOLISM; LUNG TRANSPLANTATION; LUNG VENTILATION PERFUSION RATIO; MALE INFERTILITY; METHEMOGLOBINEMIA; MORTALITY; NAUSEA; NEWBORN CARE; NONHUMAN; OXYGEN THERAPY; PAIN; PNEUMOTHORAX; PORTOPULMONARY HYPERTENSION; PULMONARY HYPERTENSION; PULMONARY SHUNT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; RESPIRATORY FAILURE; RESPIRATORY THERAPIST; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; SYSTEMIC CIRCULATION; TERATOGENESIS; TESTIS ATROPHY; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VASODILATATION; VOMITING; CLASSIFICATION; EVIDENCE BASED MEDICINE; PATHOPHYSIOLOGY; PULMONARY ARTERY; REVIEW; TREATMENT OUTCOME; UNITED STATES;

EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION, PULMONARY; PULMONARY ARTERY; TREATMENT OUTCOME; UNITED STATES; VASODILATOR AGENTS;

EID: 34548589071     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (198)

1. Levine DJ. Diagnosis and management of pulmonary hypertension: implications for respiratory care. Respir Care 2006;51(4):368-381.
2. Lowson SM. Inhaled alternatives to nitric oxide. Crit Care Med 2005;33(3):S188-S195.
3. Therese P. Persistent pulmonary hypertension of the newborn. Paediatr Respir Rev 2006;7(1):S175-S176.
4. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(1):S35-S62.
5. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25(24):2243-2278.
6. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115(5):343-349.
7. Moudgil R, Michelakis ED, Archer SL. Hypoxic pulmonary vasoconstriction. J Appl Physiol 2005;98(1):390-403.
8. Marshall BE, Marshall C, Frasch F, Hanson CW. Role of hypoxic pulmonary vasoconstriction in pulmonary gas exchange and blood flow distribution. 1. Physiologic concepts. Intensive Care Med 1994; 20(4):291-297.
9. Marshall BE, Hanson CW, Frasch F, Marshall C. Role of hypoxic pulmonary vasoconstriction in pulmonary gas exchange and blood flow distribution. 2. Pathophysiology. Intensive Care Med 1994; 20(5):379-389.
10. Gibbs JSR, Higenbottam TW. British Cardiac Society Medical Practice Committee. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001;86(1):S1-S13.
11. Roberts DH, Lepore JJ, Maroo A, Semigran MJ, Ginns LC. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest 2001;120(5):1547-1555.
12. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981;36(10):752-758.
13. Dallari R, Barozzi G, Pinelli G, Merighi V, Grandi P, Manzotti M, Tartoni PL. Predictors of survival in subjects with chronic obstructive pulmonary disease treated with long-term oxygen therapy. Respiration 1994;61(1):8-13.
14. Wuertemberger G, Zielinsky J, Sliwinsky P, Auw-Haedrich C, Matthys H. Survival in chronic obstructive pulmonary disease after diagnosis of pulmonary hypertension related to long-term oxygen therapy. Lung 1990;168 Suppl:S762-S769.
15. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985;131(4):493-498.
16. Cranston JM, Crockett AJ, Moss JR, Alpers JH Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;(4):CD001744.
17. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327(2):76-81.
18. Rubin LJ, Nicod P, Hillis LD, Firth BG.Treatment of primary pulmonary hypertension with nifedipine: a hemodynamic and scintigraphic evaluation. Ann Intern Med 1983;99(4):433-438.
19. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987;76(1):135-141.
20. Malik AS, Warshafsky S, Lehrman S. Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension. Arch Intern Med 1997;157(6):621-625.
21. Kalra L, Bone MF. Effect of nifedipine on physiologic shunting and oxygenation in chronic obstructive pulmonary disease. Am J Med 1993;94(4):419-423.
22. Packer M. Vasodilator therapy for primary pulmonary hypertension: limitations and hazards. Ann Intern Med 1985;103(2):258-270.
23. Tsuda T, Hatta M, Ishikawa K, Nakagawa T, Mabuchi N, Ando H, Nishida O. Inhalation of calcium channel blocking agents protects against methacholine-induced bronchoconstriction. J Anesth 1993;7(4):397-404.
24. Cuss FM, Barnes PJ.The effect of inhaled nifedipine on bronchial reactivity to histamine in man. J Allergy Clin Immunol 1985;76(5):718-723.
25. Wang T, El Kebir D, Blaise G. Inhaled nitric oxide in 2003: a review of its mechanisms of action. Can J Anaesth 2003;50(8):839-846.
26. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288(5789):373-376.
27. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987;84(24):9265-9269.
28. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329(27):2002-2012.
29. Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation 2004;109(25):3106-3111.
30. Weinberger B, Laskin DL, Heck DE, Laskin JD. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59(1):5-16.
31. Das S, Kumar KN. Nitric oxide: its identity and role in blood pressure control. Life Sci 1995;57(17):1547-1556.
32. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43(2):109-142.
33. Stamler JS, Loh E, Roddy MA, et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994;89(5):2035-2040.
34. Abman SH, Chatfield BA, Hall SL, McMurtry IF. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol 1990;259(6):1921-1927.
35. Villamor E, Le Cras TD, Horan MP, Halbower AC, Tuder RM, Abman SH. Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus. Am J Physiol 1997;272(5):1013-1020.
36. Chambers DC, Carpenter DA, Ayres JG. Exchange dynamics of nitric oxide in the human nose. J Appl Physiol 2001;91(5):1924-1930.
37. Dillon WC, Hampl V, Shultz PJ, Rubins JB, Archer SL. Origins of breath nitric oxide in humans. Chest 1996;110(4):930-938.
38. Schedin U, Frostell C, Persson MG, Jakobsson J, Andersson G, Gustafsson LE. Contribution from upper and lower airways to exhaled endogenous nitric oxide in humans. Acta Anaesthesiol Scand 1995;39(3):327-332.
39. Lundberg JO, Settergren G, Gelinder S, Lundberg JM, Alving K, Weitzberg E. Inhalation of nasally derived nitric oxide modulates pulmonary function in humans. Acta Physiol Scand 1996;158(4):343-347.
40. Lundberg JO, Lundberg JM, Settergren G, Alving K, Weitzberg E. Nitric oxide, produced in the upper airways, may act in an aerocrine fashion to enhance pulmonary oxygen uptake in humans. Acta Physiol Scand 1995;155(4):467-468.
41. Settergren G, Angdin M, Astudillo R, Gelinder S, Liska J, Lundberg JO, Weitzberg E. Decreased pulmonary vascular resistance during nasal breathing: modulation by endogenous nitric oxide from the paranasal sinuses. Acta Physiol Scand 1998;163(3):235-239.
42. Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, Hauser DL, Criner GJ, et al. Effects of inhaled nitric oxide in patients with acute randomized phase II trial: Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med 1998;26(1):15-23.
43. Taylor RW, Zimmerman JL, Dellinger RP, Straube RC, Criner GJ, Davis K Jr, et al; Inhaled Nitric Oxide in ARDS Study Group. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA 2004;291(13):1603-1609.
44. Steudel W, Hurford WE, Zapol WM. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology 1999;91(4):1090-1121.
45. Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12(2):265-270.
46. Mourgeon E, Levesque E, Duveau C, Law-Koune JD, Charbit B, Ternissien E, et al. Factors influencing indoor concentrations of nitric oxide in a Parisian intensive care unit. Am J Respir Crit Care Med 1997;156(5):1692-1695.
47. Norman V, Keith CH. Nitrogen oxides in tobacco smoke. Nature 1965;205(4974):915-916.
48. Tan PS, Genc F, Delgado E, Kellum JA, Pinsky MR .Nitric oxide contamination of hospital compressed air improves gas exchange in patients with acute lung injury. Intensive Care Med 2002;28(8):1064-1072.
49. Benzing A, Loop T, Mols G, Geiger K. Unintended inhalation of nitric oxide by contamination of compressed air: physiologic effects and interference with intended nitric oxide inhalation in acute lung injury. Anesthesiology 1999;91(4):945-950.
50. Lum LC, Tan PS, Saville A, Venkataraman ST, Pinsky MR. Occult nitric oxide inhalation improves oxygenation in mechanically ventilated children. J Pediatr 1998;133(5):613-616.
51. Pinsky MR, Genc F, Lee KH, Delgado E. Contamination of hospitalcompressed air with nitric oxide: unwitting replacement therapy. Chest 1997;111(6):1759-1763.
52. Lee KH, Tan PS, Rico P, Delgado E, Kellum JA, Pinsky MR. Low levels of nitric oxide as contaminant in hospital compressed air: physiologic significance? Crit Care Med 1997;25(7):1143-1146.
53. Snell GI, Salamonsen RF, Bergin P, Esmore DS, Khan S, Williams TJ. Inhaled nitric oxide used as a bridge to heart-lung transplantation in a patient with end-stage pulmonary hypertension. Am J Respir Crit Care Med 1995;151(4):1263-1266.
54. Vonbank K, Ziesche R, Higenbottam TW, Stiebellehner L, Petkov V, Schenk P, et al. Controlled prospective randomized trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax 2003;58(4):289-293.
55. Perez-Penate G, Julia-Serda G, Pulido-Duque JM, Gorriz-Gomez E, Cabrera-Navarro P. One-year continuous inhaled nitric oxide for primary pulmonary hypertension. Chest 2001;119(3):970-973.
56. Channick RN, Newhart JW, Johnson FW, Williams PJ, Auger WR, Fedullo PF, Moser KM. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension. Chest 1996;109(6):1545-1549.
57. Yung GL, Kriett JM, Jamieson SW, Johnson FW, Newhart J, Kinninger K, Channick RN. Outpatient inhaled nitric oxide in a patient with idiopathic pulmonary fibrosis: a bridge to lung transplantation. J Heart Lung Transplant 2001;20(11):1224-1227.
58. NIOSH recommendations for occupational safety and health standards 1988. MMWR Morb Mortal Wkly Rep 1988;37(7):S1-S29.
59. Sokol GM, Van Meurs KP, Wright LL, Rivera O, Thorn WJ 3rd, Chu PM, Sams RL. Nitrogen dioxide formation during inhaled nitric oxide therapy. Clin Chem 1999;45(3):382-387.
60. Frampton MW, Morrow PE, Cox C, Gibb FR, Speers DM, Utell MJ. Effects of nitrogen dioxide exposure on pulmonary function and airway reactivity in normal humans. Am Rev Respir Dis 1991;143(3):522-527.
61. Malatinsky J, Kadlic T, Kovacik V. Acute poisoning by higher nitrogen oxides. Anesth Analg 1973;52(1):94-99.
62. INO Therapeutics, INO Max, package insert. 2006.
63. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2006; 18(4):CD000399.
64. Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2006;(1):CD000509.
65. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, et al. NO CLD Study Group. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006; 355(4):343-353.
66. Dani C, Bertini G, Pezzati M, Filippi L, Cecchi A, Rubaltelli FF. Inhaled nitric oxide in very preterm infants with severe respiratory distress syndrome. Acta Paediatr 2006;95(9):1116-1123.
67. Dobyns EL, Cornfield DN, Anas NG, Fortenberry JD, Tasker RC, Lynch A, et al. Multicenter randomized controlled trial of the effects of inhaled nitric oxide therapy on gas exchange in children with acute hypoxemic respiratory failure. J Pediatr 1999;134(4):406-412.
68. Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study: the European Study Group of Inhaled Nitric Oxide. Intensive Care Med 1999;25(9):911-919.
69. Troncy E, Collet JP, Shapiro S, Guimond JG, Blair L, Ducruet T, et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med 1998;157(5):1483-1488.
70. Michael JR, Barton RG, Saffle JR, Mone M, Markewitz BA, Hillier K, et al. Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med 1998;157(5):1372-1380.
71. Sokol J, Jacobs SE, Bohn D. Inhaled nitric oxide for acute hypoxemic respiratory failure in children and adults. Cochrane Database Syst Rev 2003;(1):CD002787.
72. Angus DC, Clermont G, Linde-Zwirble WT, Musthafa AA, Dremsizov TT, Lidicker J, Lave JR. Healthcare costs and long-term outcomes after acute respiratory distress syndrome: a phase III trial of inhaled nitric oxide. Crit Care Med 2006;34(12):2883-2890.
73. George I, Xydas S, Topkara VK, Ferdinando C, Barnwell EC, Gableman L, et al. Clinical indication for use and outcomes after inhaled nitric oxide therapy. Ann Thorac Surg 2006;82(6):2161-2169.
74. Oz MC, Ardehali A. Collective review: perioperative uses of inhaled nitric oxide in adults. Heart Surg Forum 2004;7(6):584-589.
75. Bizzarro M, Gross I. Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease. Cochrane Database Syst Rev 2005;(4):CD005055.
76. Rea RS, Ansani NT, Seybert AL. Role of inhaled nitric oxide in adult heart or lung transplant recipients. Ann Pharmacother 2005; 39(5):913-917.
77. Hospira Inc. Sodium nitroprusside, package insert. Oct 2006.
78. Coddens J, Delooft T, Vandenbroucke G. Effects of dobutamine and/or nitroprusside on the pulmonary circulation in patients with pulmonary hypertension secondary to end-stage heart failure. J Cardiothorac Vasc Anesth 1993;7(3):321-325.
79. Schutte H, Grimminger F, Otterbein J, Spriestersbach R, Mayer K, Walmrath D, Seeger W. Efficiency of aerosolized nitric oxide donor drugs to achieve sustained pulmonary vasodilation. J Pharmacol Exp Ther 1997;282(2):985-994.
80. Meadow W, Rudinsky B, Bell A, Hipps R. Effects of nebulized nitroprusside on pulmonary and systemic hemodynamics during pulmonary hypertension in piglets. Pediatr Res 1998;44(2):181-186.
81. Yu XQ, Saugstad OD. Nebulization of sodium nitroprusside in lung-lavaged newborn piglets. Pediatr Res 1999;45(2):255-259.
82. Schreiber MD, Dixit R, Rudinsky B, Hipps R, Morgan SE, Keith A, Meadow W. Direct comparison of the effects of nebulized nitroprusside versus inhaled nitric oxide on pulmonary and systemic hemodynamics during hypoxia-induced pulmonary hypertension in piglets. Crit Care Med 2002;30(11):2560-2565.
83. Palhares DB, Figueiredo CS, Moura AJ. Endotracheal inhalatory sodium nitroprusside in severely hypoxic newborns. J Perinat Med 1998;26(3):219-224.
84. Mestan KK, Carlson AD, White M, Powers JA, Morgan S, Meadow W, Schreiber MD. Cardiopulmonary effects of nebulized sodium nitroprusside in term infants with hypoxic respiratory failure. J Pediatr 2003;143(5):640-643.
85. Gong F, Shiraishi H, Kikuchi Y, Hoshina M, Ichihashi K, Sato Y, Momoi MY. Inhalation of nebulized nitroglycerin in dogs with experimental pulmonary hypertension induced by U46619. Pediatr Int 2000;42(3):255-258.
86. Bando M, Ishii Y, Kitamura S, Ohno S. Effects of inhalation of nitroglycerin on hypoxic pulmonary vasoconstriction. Respiration 1998;65(1):63-70.
87. Goyal P, Kiran U, Chauhan S, Juneja R, Choudhary M. Efficacy of nitroglycerin inhalation in reducing pulmonary arterial hypertension in children with congenital heart disease. Br J Anaesth 2006;97(2):208-214.
88. Yurtseven N, Karaca P, Kaplan M, Ozkul V, Tuygun AK, Aksoy T, et al. Effect of nitroglycerin inhalation on patients with pulmonary hypertension undergoing mitral valve replacement surgery. Anesthesiology 2003;99(4):855-858.
89. Omar HA, Gong F, Sun MY, Einzig S. Nebulized nitroglycerin in children with pulmonary hypertension secondary to congenital heart disease. W V Med J 1999;95(2):74-75.
90. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 2005;97(7):618-628.
91. Elkayam U, Kulick D, McIntosh N, Roth A, Hsueh W, Rahimtoola SH. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation 1987;76(3):577-584.
92. Hospira Inc. Nitroglycerin, injection solution, package insert. 2004. http://dailymed.nlm.nih.gov/dailymed/drugInfo
93. Dabrowska K, Hehre D, Young KC, Navarette C, Ladino JF, Bancalari E, Suguihara C. Effects of a nebulized NONOate, DPTA/NO, on group B streptococcus-induced pulmonary hypertension in newborn piglets. Pediatr Res 2005;57(3):378-383.
94. Young KC, Ladino J, Navarrete C, Dabrowska K, Hehre D, Bancalari E, Suguihara C. The effect of a nebulized NO donor, DPTA/NO, on acute hypoxic pulmonary hypertension in newborn piglets. Biol Neonate 2004;85(3):195-202.
95. Brilli RJ, Krafte-Jacobs B, Smith DJ, Passerini D, Moore L, Ballard ET. Aerosolization of novel nitric oxide donors selectively reduce pulmonary hypertension. Crit Care Med 1998;26(8):1390-1396.
96. Jacobs BR, Brilli RJ, Ballard ET, Passerini DJ, Smith DJ. Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury. Am J Respir Crit Care Med 1998;158(5):1536-1542.
97. Lam CF, Van Heerden PV, Blott J, Roberts B, Ilett KF. The selective pulmonary vasodilatory effect of inhaled DETA/NO, a novel nitric oxide donor, in ARDS: a pilot human trial. J Crit Care 2004;19(1):48-53.
98. Kerins DM, Murray R, FitzGerald GA. Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility. Prog Hemost Thromb 1991;10:307-337.
99. Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O, Barst RJ. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12):S56-S61.
100. Fischer LG, Van Aken H, Burkle H. Management of pulmonary hypertension: physiological and pharmacological considerations for anesthesiologists. Anesth Analg 2003;96(6):1603-1616.
101. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327(2):70-75.
102. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159(6):1925-1932.
103. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000;132(6):425-434.
104. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990;112(7):485-491.
105. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338(5):273-277.
106. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334(5):296-302.
107. GlaxoSmithKline, Flolan product information, April 2006 108. Siobal M. Aerosolized prostacyclins. Respir Care 2004;49(6):640-652.
108. Siobal MS, Kallet RH, Pittet JF, Warnecke EL, Kraemer RW, Venkayya RV, Tang JF. Description and evaluation of a delivery system for aerosolized prostacyclin. Respir Care 2003;48(8):742-753.
109. Van Heerden PV, Barden A, Michalopoulos N, Bulsara MK, Roberts BL. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest 2000;117(3):819-827.
110. Pappert D, Busch T, Gerlach H, Lewandowski K, Radermacher P, Rossaint R. Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology 1995;82(6):1507-1511.
111. Saji T, Ozawa Y, Ishikita T, Matsuura H, Matsuo N. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996;78(2):244-247.
112. Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997;349(9062):1365.
113. Nagaya N, Uematsu M, Okano Y, Satoh T, Kyotani S, Sakamaki F, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999;34(4):1188-1192.
114. Vizza CD, Sciomer S, Morelli S, Lavalle C, Di Marzio P, Padovani D, et al. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart 2001;86(6):661-665.
115. Ono F, Nagaya N, Kyotani S, Oya H, Nakanishi N, Miyatake K. Hemodynamic and hormonal effects of beraprost sodium, an orally active prostacyclin analogue, in patients with secondary precapillary pulmonary hypertension. Circ J 2003;67(5):375-378.
116. Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al; Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39(9):1496-1502.
117. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, et al. Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41(12):2119-2125.
118. Ishikawa S, Kawasaki A, Neya K, Kugawa S, Hayama T, Ueda K. Beraprost sodium-induced hypotension in two patients after cardiac surgery. Int Heart J 2006;47(2):319-323.
119. Durongpisitkul K, Laoprasitiporn D, Layangool T, Sittiwankul R, Panamonta M, Mokrapong P; Thailand Multicenter Study. Comparison of the acute pulmonary vasodilating effect of beraprost sodium and nitric oxide in congenital heart disease. Circ J 2005;69(1):61-64.
120. Actelion Pharmaceuticals, Iloprost product information, Jan 2006.
121. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996;124(9):820-824.
122. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et el; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347(5):322-329.
123. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000;35(1):176-182.
124. Rimensberger PC, Spahr-Schopfer I, Berner M, Jaeggi E, Kalangos A, Friedli B, Beghetti M. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 2001;103(4):544-548.
125. Higenbottam TW, Butt AY, Dinh-Xaun AT, Takao M, Cremona G, Akamine S. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 1998;79(2):175-179.
126. Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, Linscheid M, Hetzer R, Ewert R. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003;24(4):356-365.
127. Hoeper MM, Spiekerkoetter E, Westerkamp V, Gatzke R, Fabel H. Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. Eur Respir J 2002;20(2):339-343.
128. Ewert R, Opitz C, Wensel R, Winkler J, Hoffken G, Frank W, Berger F, et al. Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension. Z Kardiol 2000;89(11):987-999.
129. Schenk P, Petkov V, Madl C, Kramer L, Kneussl M, Ziesche R, Lang I. Aerosolized iloprost therapy could not replace long-term IV epoprostenol (prostacyclin) administration in severe pulmonary hypertension. Chest 2001;119(1):296-300.
130. Opitz CF, Wensel R, Winkler J, Halank M, Bruch L, Kleber FX, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005;26(18):1895-1902.
131. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, et al; Treprostinil Study Group. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41(2):293-299.
132. Lang I, Gomez-Sanchez M, Kneussl M, Naeije R, Escribano P, Skoro-Sajer N, Vachiery JL. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006;129(6):1636-1643.
133. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebocontrolled trial. Am J Respir Crit Care Med 2002;165(6):800-804.
134. Wade M, Hunt TL, Lai AA. Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. J Cardiovasc Pharmacol 2003;41(6):908-915.
135. Vachiery JL, Hill N, Zwicke D, Barst R, Blackburn S, Naeije R. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002;121(5):1561-1565.
136. Sandifer BL, Brigham KL, Lawrence EC, Mottola D, Cuppels C, Parker RE. Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation. J Appl Physiol 2005;99(6):2363-2368.
137. Voswinckel R, Ghofrani HA, Grimminger F, Seeger W, Olschewski H. Inhaled treprostinil for treatment of chronic pulmonary arterial hypertension. Ann Intern Med 2006;144(2):149-150.
138. Voswinckel R, Enke B, Reichenberger F, Kohstall M, Kreckel A, Krick S, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006;48(8):1672-1681.
139. United Therapeutics Website. Available at: http://www.unither.com/index. asp. (Accessed Feb 2007)
140. Aradigm Website. Available at: http://www.aradigm.com/pipeline/ applications.html. (Accessed Feb 2007)
141. Dhand R. New frontiers in aerosol delivery during mechanical ventilation. Respir Care 2004;49(6):666-677.
142. Pharmacia & Upjohn, Alprotadil Injection, package insert, Aug 2002.
143. Putensen C, Hormann C, Kleinsasser A, Putensen-Himmer G. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998;157(6):1743-1747.
144. Kermode J, Butt W, Shann F. Comparison between prostaglandin E1 and epoprostenol (prostacyclin) in infants. Br Heart J 1991;66(2):175-178.
145. Meyer J, Theilmeier G, Van Aken H, Bone HG, Busse H, Waurick R, et al. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesth Analg 1998;86(4):753-758.
146. Sood BG, Delaney-Black V, Aranda JV, Shankaran S. Aerosolized PGE1: a selective pulmonary vasodilator in neonatal hypoxemic respiratory failure results of a Phase I/II open label clinical trial. Pediatr Res 2004;56(4):579-585.
147. Walmrath D, Schermuly R, Pilch J, Grimminger F, Seeger W. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur Respir J 1997;10(5):1084-1092.
148. Kleen M, Habler O, Hofstetter C, Pusch R, Mueller M, Welte M, Zwissler B. Efficacy of inhaled prostanoids in experimental pulmonary hypertension. Crit Care Med 1998;26(6):1103-1109.
149. Sood BG, Glibetic M, Aranda JV, Delaney-Black V, Chen X, Shankaran S. Systemic levels following PGE1 inhalation in neonatal hypoxemic respiratory failure. Acta Paediatr 2006;95(9):1093-1098.
150. Eichelbronner O, Reinelt H, Wiedeck H, Mezody M, Rossaint R, Georgieff M, Radermacher P. Aerosolized prostacyclin and inhaled nitric oxide in septic shock different effects on splanchnic oxygenation? Intensive Care Med 1996;22(9):880-887.
151. Reffelmann T, Kloner RA. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr Pharm Des 2006;12(27):3485-3494.
152. Lewis GD, Semigran MJ. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. Curr Heart Fail Rep 2004;1(4):183-189.
153. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353(20):2148-2157.
154. Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006;151(4):851.e1-5.
155. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004;43(7):1149-1153.
156. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 2006;117(4):1077-1083.
157. Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, openlabel, pilot study. Circulation 2005;111(24):3274-3280.
158. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999;91(1):307-310.
159. Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 2006;174(9):1042-1047.
160. Madden BP, Allenby M, Loke TK, Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 2006;44(5):372-376.
161. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105(20):2398-2403.
162. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004;44(7):1488-1496.
163. Schermuly RT, Ghofrani HA, Enke B, Weissmann N, Grimminger F, Seeger W, et al. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Respir Crit Care Med 1999;160(5):1500-1506.
164. Schermuly RT, Roehl A, Weissmann N, Ghofrani HA, Schudt C, Tenor H, et al. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. J Pharmacol Exp Ther 2000;292(2):512-520.
165. Schermuly RT, Krupnik E, Tenor H, Schudt C, Weissmann N, Rose F, et al. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: maintenance of lung selectivity. Am J Respir Crit Care Med 2001;164(9):1694-1700.
166. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, et al. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med 2002;30(11):2489-2492.
167. Ichinose F, Erana-Garcia J, Hromi J, Raveh Y, Jones R, Krim L, et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 2001;29(5):1000-1005.
168. Ichinose F, Adrie C, Hurford WE, Bloch KD, Zapol WM. Selective pulmonary vasodilation induced by aerosolized zaprinast. Anesthesiology 1998;88(2):410-416.
169. Sablotzki A, Starzmann W, Scheubel R, Grond S, Czeslick EG. Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates. Can J Anaesth 2005;52(10):1076-1082.
170. Pfizer Labs. Revatio (sildenafil) package insert; July 2006.
171. Kim H, Yung GL, Marsh JJ, Konopka RG, Pedersen CA, Chiles PG, et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J 2000;15(4):640-648.
172. Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir Res 2001;2(2):90-101.
173. Galie N, Grigioni F, Bacchi-Reggiani L, et al. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur J Clin Invest 1996;26:273.
174. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328(24):1732-1739.
175. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001;120(5):1562-1569.
176. Benigni A, Remuzzi G. Endothelin antagonists. Lancet 1999;353(9147):133- 138.
177. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000;102(19):2434-2340.
178. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79(6):2122-2131.
179. Hill NS, Warburton RR, Pietras L, Klinger JR. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol 1997;83(4):1209-1215.
180. Pearl JM, Wellmann SA, McNamara JL, Lombardi JP, Wagner CJ, Raake JL, Nelson DP. Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function. Ann Thorac Surg 1999;68(5):1714-1721.
181. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896-903.
182. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo controlled study. Lancet 2001;358(9288):1119-1123.
183. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124(1):247-254.
184. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S; STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47(10):2049-2056.
185. O'Callaghan DS, Gaine SP. Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. Int J Clin Pract 2006;60(4):475-481.
186. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46(3):529-535.
187. Donaubauer B, Busch T, Lachmann R, Deja M, Petersen B, Francis R, et al. Low-dose inhalation of an endothelin-A receptor antagonist in experimental acute lung injury: ET-1 plasma concentration and pulmonary inflammation. Exp Biol Med (Maywood) 2006;231(6):960-966.
188. Deja M, Busch T, Wolf S, Donaubauer B, Petersen B, Skomrock J, et al. Inhalation of the endothelin-A receptor antagonist LU-135252 at various doses in experimental acute lung injury. J Cardiovasc Pharmacol 2004;44(1):S151-S155.
189. Deja M, Wolf S, Busch T, Petersen B, Jaghzies U, Boemke W, Kaisers U. The inhaled ET(A) receptor antagonist LU-135252 acts as a selective pulmonary vasodilator. Clin Sci (Lond) 2002;103(48):S21-S24.
190. Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. The Cochrane Database Syst Rev 2006;3:CD004434.
191. Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 2006;48(7):1433-1437.
192. Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24(3):353-359.
193. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003;22(2):330-334.
194. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42(1):158-164.
195. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136(7):515-522.
196. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104(11):1218-1222.
197. Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, Semigran MJ. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005;127(5):1647-1653.
198. Lepore JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM, et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002;90(6):677-680.